GALT and Global developmental delay: For the galactosemia variant, the D/G phenotype of GALT activity in which at least one mutation is the c.940A > G (p.Asn314Asp) allele with the enzyme activity between 5% and 50% of normal control values and with which there is no evidence for hepatocellular damage, cataract, or developmental delays during infancy, the need to restrict dietary galactose is uncertain [19],[20].